This HTML5 document contains 72 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
n2http://linked.opendata.cz/resource/drugbank/drug/
n17http://linked.opendata.cz/resource/drugbank/drug/DB00870/identifier/kegg-drug/
dctermshttp://purl.org/dc/terms/
n19http://linked.opendata.cz/resource/drugbank/drug/DB00870/identifier/drugbank/
n23http://linked.opendata.cz/resource/mesh/concept/
n24http://linked.opendata.cz/resource/drugbank/company/
foafhttp://xmlns.com/foaf/0.1/
n13http://linked.opendata.cz/resource/drugbank/drug/DB00870/identifier/national-drug-code-directory/
n18http://linked.opendata.cz/resource/drugbank/drug/DB00870/identifier/chemspider/
n15http://bio2rdf.org/drugbank:
admshttp://www.w3.org/ns/adms#
n21http://linked.opendata.cz/resource/drugbank/drug/DB00870/identifier/chebi/
n5http://www.drugs.com/mtm/
n9http://wifo5-03.informatik.uni-mannheim.de/drugbank/resource/drugs/
n25http://linked.opendata.cz/resource/drugbank/drug/DB00870/identifier/wikipedia/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
owlhttp://www.w3.org/2002/07/owl#
n14http://linked.opendata.cz/resource/drugbank/drug/DB00870/identifier/pharmgkb/
n22http://linked.opendata.cz/ontology/mesh/
n3http://linked.opendata.cz/ontology/drugbank/
n16http://linked.opendata.cz/resource/drugbank/drug/DB00870/identifier/kegg-compound/
n7http://linked.opendata.cz/resource/drugbank/property/
n20http://linked.opendata.cz/resource/drugbank/drug/DB00870/identifier/bindingdb/
xsdhhttp://www.w3.org/2001/XMLSchema#
n11http://linked.opendata.cz/resource/drugbank/drug/DB00870/identifier/pubchem-compound/
n26http://linked.opendata.cz/ontology/sukl/drug/
n27http://linked.opendata.cz/resource/atc/
n12http://linked.opendata.cz/resource/drugbank/drug/DB00870/identifier/pubchem-substance/

Statements

Subject Item
n2:DB00870
rdf:type
n3:Drug
n3:description
An ibuprofen-type anti-inflammatory analgesic and antipyretic. It inhibits prostaglandin synthesis and has been proposed as an anti-arthritic. It is no longer approved for use in the United States.
n3:group
approved withdrawn
n3:indication
Used as eye drops to inhibit the miosis (pupil constriction) that may occur during ocular surgery.
n3:manufacturer
n24:271B5330-363D-11E5-9242-09173F13E4C5
owl:sameAs
n9:DB00870 n15:DB00870
dcterms:title
Suprofen
adms:identifier
n11:5359 n12:46508210 n13:0065-0348-25 n14:PA451569 n16:C07320 n17:D00452 n18:5166 n19:DB00870 n20:50090676 n21:9362 n25:Suprofen
n3:mechanismOfAction
Suprofen binds to the cyclooxygenase-1 (COX-1) and cyclooxygenase-2 (COX-2) isoenzymes, preventing the synthesis of prostaglandins and reducing the inflammatory response. Cyclooxygenase catalyses the formation of prostaglandins and thromboxane from arachidonic acid (itself derived from the cellular phospholipid bilayer by phospholipase A<sub>2</sub>). Prostaglandins act (among other things) as messenger molecules in the process of inflammation. The overall result is a reduction in pain and inflammation in the eyes and the prevention of pupil constriction during surgery. Normally trauma to the anterior segment of the eye (especially the iris) increases endogenous prostaglandin synthesis which leads to constriction of the iris sphincter.
n3:synonym
Suprofen 4-(2-Thenoyl)hydratropsaeure Suprofene Suprofeno alpha-Methyl-4-(2-thienylcarbonyl)benzeneacetic acid 2-(4-(2-Thenoyl)phenyl)propionsaeure SUTOPROFEN PROFENAL (+-)-2-(P-(2-Thenoyl)phenyl)propionic acid 2-[4-(Thiophene-2-carbonyl)-phenyl]-propionic acid Suprofenum P-2-Thenoylhydratropic acid Suprofène
n3:toxicity
Symptoms of overdose include bleeding in the eye or redness or swelling of the eye or the eyelid, blurred vision or other change in vision, fever or chills, itching or tearing, nausea or vomiting, pain, sensitivity to light, shortness of breath, sticky or matted eyelashes, swelling of face, throbbing pain, tightness in chest, troubled breathing, and wheezing.
n3:proteinBinding
20%
n22:hasConcept
n23:M0020851
foaf:page
n5:suprofen-ophthalmic.html
n3:IUPAC-Name
n7:271B5335-363D-11E5-9242-09173F13E4C5
n3:InChI
n7:271B533B-363D-11E5-9242-09173F13E4C5
n3:Molecular-Formula
n7:271B533A-363D-11E5-9242-09173F13E4C5
n3:Molecular-Weight
n7:271B5337-363D-11E5-9242-09173F13E4C5
n3:Monoisotopic-Weight
n7:271B5338-363D-11E5-9242-09173F13E4C5
n3:SMILES
n7:271B5339-363D-11E5-9242-09173F13E4C5
n3:Water-Solubility
n7:271B534B-363D-11E5-9242-09173F13E4C5 n7:271B5333-363D-11E5-9242-09173F13E4C5
n3:logP
n7:271B534D-363D-11E5-9242-09173F13E4C5 n7:271B5334-363D-11E5-9242-09173F13E4C5 n7:271B5331-363D-11E5-9242-09173F13E4C5
n3:logS
n7:271B5332-363D-11E5-9242-09173F13E4C5
n3:pKa
n7:271B534E-363D-11E5-9242-09173F13E4C5
n26:hasATCCode
n27:M01AE07
n3:H-Bond-Acceptor-Count
n7:271B5341-363D-11E5-9242-09173F13E4C5
n3:H-Bond-Donor-Count
n7:271B5342-363D-11E5-9242-09173F13E4C5
n3:InChIKey
n7:271B533C-363D-11E5-9242-09173F13E4C5
n3:Polar-Surface-Area--PSA-
n7:271B533D-363D-11E5-9242-09173F13E4C5
n3:Polarizability
n7:271B533F-363D-11E5-9242-09173F13E4C5
n3:Refractivity
n7:271B533E-363D-11E5-9242-09173F13E4C5
n3:Rotatable-Bond-Count
n7:271B5340-363D-11E5-9242-09173F13E4C5
n3:affectedOrganism
Humans and other mammals
n3:casRegistryNumber
40828-46-4
n3:category
n3:Bioavailability
n7:271B5347-363D-11E5-9242-09173F13E4C5
n3:Ghose-Filter
n7:271B5349-363D-11E5-9242-09173F13E4C5
n3:MDDR-Like-Rule
n7:271B534A-363D-11E5-9242-09173F13E4C5
n3:Melting-Point
n7:271B534C-363D-11E5-9242-09173F13E4C5
n3:Number-of-Rings
n7:271B5346-363D-11E5-9242-09173F13E4C5
n3:Physiological-Charge
n7:271B5345-363D-11E5-9242-09173F13E4C5
n3:Rule-of-Five
n7:271B5348-363D-11E5-9242-09173F13E4C5
n3:Traditional-IUPAC-Name
n7:271B5336-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-acidic-
n7:271B5343-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-basic-
n7:271B5344-363D-11E5-9242-09173F13E4C5